Superworth

Spruce Biosciences free cash flow SPRB

Cash from operations less capital spending, by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
−$22.3M
Fiscal year 2024
n/a

Spruce Biosciences' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was −$22.3M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2024n/an/a
FY2023n/an/a
FY2022n/an/a
FY2021−$36Mn/a
FY2020n/an/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$22.3Mn/an/a
Q1 FY26−$8.7Mn/an/a
Q2 FY25−$8.8Mn/an/a
Q1 FY25−$12.7Mn/an/a
Q4 FY24−$20.7Mn/an/a
Q4 FY23−$11.2Mn/an/a
Q3 FY23−$12.3Mn/an/a
Q4 FY22−$11.7Mn/an/a
Q3 FY22−$8.6Mn/an/a
Q4 FY21−$9.8Mn/a−$36M
Q3 FY21−$7.7Mn/a−$35.5M
Q2 FY21−$9.7Mn/a−$35.4M

Against its peers

Companies in Drug Manufacturers - General nearest Spruce Biosciences' size, closest first, today.

CompanyFree cash flow yield
SPRBSpruce Biosciencesn/m
NATRNatures Sunshine Products8.5%
LFVNLifevantage9.1%
SPROSpero Therapeuticsn/m
ATNMActinium Pharmaceuticalsn/m
ARVNArvinas−43.7%
PBYIPuma Biotechnology7.2%
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics5.6%
CRMDCorMedixn/m
COLLCollegium Pharmaceuticaln/m
Peer median7.2%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Spruce Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.